|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 700 13th Street NW, 2nd Floor |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 313715-330
|
||||||||
|
6. House ID# 393840007
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Allegra M. Han |
Date | 7/20/2022 11:09:15 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements; use of step therapy in Medicare and health insurance coverage; including related provisions in H.R. 5376 the Build Back Better Act, including provisions regarding Lowering Prices Through Drug Price Negotiation, establishment of a Drug Price Negotiation Program, and Medicare Inflation Rebates, including related provisions in Sections 139001, 139002, 139101, and 139102, and related provisions in the Senate Finance Committee posted amendment to H.R. 5376; and S. 464/H.R. 2163, the Safe Step Act; and antibiotic development incentives, including related provisions in H.R. 4172, P.L. 117-57, to encourage the development and use of certain antimicrobial drugs and H.R. 3932, to establish a program to develop antimicrobial innovations.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including the Most Favored Nation demonstration.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Denise |
Henry Morrisey |
|
|
|
Shannon |
Finley |
|
|
|
Sara |
Franko |
|
|
|
Luke |
Hatzis |
|
|
|
Martin |
Gold |
|
|
|
Ann |
Jablon |
|
|
|
Aaron |
Cohen |
|
|
|
Caitlin |
Canter |
|
|
|
Robert |
Diamond |
|
|
|
Jeffrey |
Carroll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Foreign parent affected by policies affecting U.S. subsidiary.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
340B Program issues and patient access to pharmaceuticals, including related provisions in Sec. 121, H.R. 2471, Consolidated Appropriations Act, 2022, P.L. 117-103.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Legislative issues associated with patient access to treatment, including the CMMI Most Favored Nation demonstration; and step therapy, including related provisions in S. 464/H.R. 2163, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines, including related provisions in H.R. 7667, Food and Drug Amendments Act and S. 4348, Food and Drug Administration Safety and Landmark Advancements Act; and improved coordination and expansion of mutual reliance agreements, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2) and H.R. 5376, the Build Back Better Act, Section 31022, Funding for Public Health and Preparedness Research, Development and Countermeasure Capacity, regarding the SNS, supply chains and domestic manufacturing.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Denise |
Henry Morrisey |
|
|
|
Shannon |
Finley |
|
|
|
Sara |
Franko |
|
|
|
Luke |
Hatzis |
|
|
|
Martin |
Gold |
|
|
|
Ann |
Jablon |
|
|
|
Aaron |
Cohen |
|
|
|
Caitlin |
Canter |
|
|
|
Joseph |
Eannello |
|
|
|
Robert |
Diamond |
|
|
|
Jeffrey |
Carroll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Foreign parent affected by policies affecting U.S. subsidiary.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods, including related provisions in H.R. 5376, the Build Back Better Act, Section 31022, Funding for Public Health and Preparedness Research, Development and Countermeasure Capacity, regarding the SNS, supply chains and domestic manufacturing.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caitlin |
Canter |
|
|
|
Robert |
Diamond |
|
|
|
Jeffrey |
Carroll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Foreign parent affected by policies affecting U.S. subsidiary.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |